Glaukos Q2 2026: Margin Lift, Revenue Forecast Boost, and a Dropless Growth Blueprint

Lead: A Quarter That Looks Like Operational Momentum, Not a One-Time Miracle

Glaukos Corporation, trading under GKOS, rolled out its second-quarter 2026 results with a tone of confidence that borders on a curriculum vitae for a medical device company: steady top-line growth, margins moving in the right direction, and a raised revenue forecast that reverberates through the year. The press release emphasizes revenue and margin expansion more than it leans on a single standout EPS figure, which leaves investors parsing for an earnings surprise in future filings. The company suggests that the core thesis—growth driven by innovative, dropless therapies—remains intact as it advances its iDose TR and Epioxa platforms.

Key Q2 2026 figures

• Total net sales: $185.6 million in Q2 2026, up 50% year over year on a reported basis (49% on a constant-currency basis).
• Glaucoma net sales: $155.2 million in Q2 2026, up 50% year over year.
• U.S. Glaucoma net sales: $118.5 million in Q2 2026, up 64% year over year.
• Gross margin: approximately 82% in Q2 2026; non-GAAP gross margin around 85%.
• Guidance for 2026: raised net sales forecast to $680 million–$700 million (from $620 million–$635 million previously).

The numbers point to a company with momentum across glaucoma-focused products and a margin profile that suggests the business is not merely riding top-line growth but also achieving improving efficiency or favorable product mix.

What’s driving the momentum

The release frames the quarter around two transformational growth drivers: iDose TR and Epioxa. The language signals that the company views these pipelines as the engines of sustainable growth, not one-off product wins. The dropless platform approach—described as a way to improve patient outcomes and standard-of-care dynamics—appears to be a core strategic differentiator, with the company underscoring progress on its development slate and market execution.

Margin strength reinforces the narrative: gross margins in the low-to-mid eighty percent range (and non-GAAP margins even higher) imply that the business is not just selling more but doing so with strong pricing power or favorable product economics. For sector peers, the signal is clear enough—investors reward durable gross-margin expansion when it accompanies top-line growth, especially in niche medical devices and specialty pharma where distribution leverage and repeatable intake matter.

Implications for GKOS and its peers

If the revenue forecast proves durable, GKOS could set a bar for peers operating in ophthalmology and chronic-eye disease management. The market will scrutinize whether the EPS line in subsequent filings aligns with the top-line strength and whether investors should expect an earnings surprise versus consensus in the forthcoming quarters. The absence of explicit EPS figures in this release means the immediate stock reaction hinges on the company’s ability to translate strong revenue growth and margin gains into meaningful per-share earnings delivery.

From a sector perspective, the emphasis on dropless therapies and a robust pipeline could elevate investor expectations for other ophthalmic players pursuing similar delivery platforms. The question for competitors is whether GKOS’s execution—across product launches, pricing, and geographic expansion—can be replicated or if GKOS enjoys a unique combination of market timing, clinical validation, and payer acceptance that sustains the current trajectory.

What the company is saying, in plain terms

“Our record second quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa,” said Thomas Burns, Glaukos chairman and chief executive officer.

The quoted sentiment captures investor-friendly themes: disciplined execution, a roadmap that prioritizes scalable product platforms, and a growth trajectory that the company believes will endure beyond a single quarter. For readers focused on earnings quality, the emphasis on a robust development pipeline and margin discipline matters just as much as the headline revenue figure.

Takeaway and what to watch next

GKOS is signaling sustainable growth through a combination of higher revenue and improved margins, with a raised 2026 revenue forecast. The key near-term questions revolve around how the company reports EPS and whether the upcoming quarter will deliver an earnings surprise versus consensus. Investors will also monitor the pace of adoption for iDose TR and Epioxa, competitive dynamics in glaucoma and corneal therapies, and any additional pipeline milestones that might extend the company’s growth runway.

In the wider eye-health sector, GKOS’s results could influence how peers price and position dropless or sustained-delivery therapies, and how aggressively the market prices growth from truly transformative platforms versus incremental product updates.